Age-related macular degeneration - Emerging pathogenetic and therapeutic concepts

Annals of Medicine

Volumn 38, Issue 7, 2006, Pages 450-471

  Gehrs, Karen M ^a   Anderson, Don H ^b   Johnson, Lincoln V ^b   Hageman, Gregory S ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Age related macular degeneration (AMD); Basal laminar deposit (BLamD); Bruch's membrane; Choroidal neovascularization; Complement Factor B (BF); Complement Factor H (CFH); Drusen; Epidemiology; Genetics; Geographic atrophy; Inflammation; Surgery

Indexed keywords

ALPHA TOCOPHEROL; ANECORTAVE; ANGIOGENESIS INHIBITOR; ANTIOXIDANT; ASCORBIC ACID; BENZOPORPHYRIN DERIVATIVE; BETA CAROTENE; BEVACIZUMAB; COMPLEMENT FACTOR H; COPPER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEGAPTANIB; RANIBIZUMAB; SQUALENE; STEROID; TRIAMCINOLONE; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; ZINC OXIDE;

BLINDNESS; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; COMPLEMENT ALTERNATIVE PATHWAY; EPIDEMIOLOGICAL DATA; EYE DISEASE; FOLLOW UP; GENETIC PREDISPOSITION; GENETIC RISK; GLAUCOMA; HEALTH SURVEY; HEREDITY; HISTOPATHOLOGY; HUMAN; INNATE IMMUNITY; LASER COAGULATION; LOW LEVEL LASER THERAPY; MENTAL HEALTH; MOLECULAR GENETICS; PALLIATIVE THERAPY; PATHOGENESIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SUBRETINAL NEOVASCULARIZATION; SURGICAL TECHNIQUE; TRANSPUPILLARY THERMOTHERAPY; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; BLINDNESS; COMPLEMENT ACTIVATION; DISEASE PROGRESSION; DRY EYE SYNDROMES; HUMANS; MACULAR DEGENERATION; MIDDLE AGED; PALLIATIVE CARE; RETINAL DRUSEN; RISK FACTORS;

EID: 33751103471     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890600946724     Document Type: Review

References (244)

1. Uhlmann RF, Larson EB, Koepsell TD, Rees TS, Duckert LG. Visual impairment and cognitive dysfunction in Alzheimer's disease. J Gen Intern Med. 1991;6: 126-32.
2. Lin MY, Gutierrez PR, Stone KL, Yaffe K, Ensrud KE, Fink HA, et al. Vision impairment and combined vision and hearing impairment predict cognitive and functional decline in older women. J Am Geriatr Soc. 2004;52:1996-2002.
3. Rovner BW, Casten RJ, Tasman WS. Effect of depression on vision function in age-related macular degeneration. Arch Ophthalmol. 2002;120:1041-4.
4. Abyad A. In-office screening for age-related hearing and vision loss. Geriatrics. 1997;52:45-6, 51-4, 57.
5. Berman K, Brodaty H. Psychosocial effects of age-related macular degeneration. Int Psychogeriatr. 2006;8:1-14.
6. Taylor H, Guymer R, Keeffe J. The Impact of Age-Related Macular Degeneration. Access Economics Pty Limited. Melbourne: University of Melbourne, 2006: p. 1-72.
7. Sunness JS. The natural history of geographic atrophy, the advanced atrophic form of age-related macular degeneration. Mol Vis. 1999;5:25.
8. Magnitude and causes of visual impairment, World Health Organization, Fact Sheet No 282.
9. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844-51.
10. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004;137:486-95.
11. Smith W, Assink J, Klein R, Mitchell P, Klaver C, Klein B, et al. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology. 2001;108:697-704.
12. Mitchell P, Smith W, Attebo K, Wang J. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology. 1995;102:1450-60.
13. VanNewkirk M, Nanjan M, Wang J, Mitchell P, Taylor H, McCarty C. The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology. 2000;107: 1593-600.
14. Wolfs RC, Borger PH, Ramrattan RS, Klaver CC, Hulsman CA, Hofman A, et al. Changing views on open-angle glaucoma: definitions and prevalences-The Rotterdam Study. Invest Ophthalmol Vis Sci. 2000;41:3309-21.
15. Mitchell P, Wang JJ, Foran S, Smith W. Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. Ophthalmology. 2002;109:1092-7.
16. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-72.
17. Taylor HR, Keeffe JE, Vu HT, Wang JJ, Rochtchina E, Pezzullo ML, et al. Vision loss in Australia. Med J Aust. 2005;182:565-8.
18. Jonasson F, Arnarsson A, Peto T, Sasaki H, Sasaki K, Bird AC. 5-year incidence of age-related maculopathy in the Reykjavik Eye Study. Ophthalmology. 2005;112:132-8.
19. Andersen N. Age-related macular degeneration among the Inuit in Greenland. Int J Circumpolar Health. 2004;63: Suppl 2: 320-3.
20. Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102:205-10.
21. Krishnaiah S, Das T, Nirmalan PK, Nutheti R, Shamanna BR, Rao GN, et al. Risk factors for age-related macular degeneration: findings from the Andhra Pradesh eye disease study in South India. Invest Ophthalmol Vis Sci. 2005;46:4442-9.
22. Munoz B, Klein R, Rodriguez J, Snyder R, West SK. Prevalence of age-related macular degeneration in a population-based sample of Hispanic people in Arizona: Proyecto VER. Arch Ophthalmol. 2005;123:1575-80.
23. Leske MC, Wu SY, Hennis A, Nemesure B, Yang L, Hyman L, et al. Nine-year incidence of age-related macular degeneration in the Barbados Eye Studies. Ophthalmology. 2006;113:29-35.
24. Wong TY, Loon SC, Saw SM. The epidemiology of age related eye diseases in Asia. Br J Ophthalmol. 2006;90:506-11.
25. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin age-related maculopathy grading system. Ophthalmology. 1991;98:1128-34.
26. Age-Related Eye Disease Study Research Group, The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. Control Clin Trials. 1999;20:573-600.
27. Davis MD, Gangnon RE, Lee LY, Hubbard LD, Klein BE, Klein R, et al. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No.17. Arch Ophthalmol. 2005;123:1484-98.
28. Ferris FL, Davis MD, Clemons TE, Lee LY, Chew EY, Lindblad AS, et al. A simplified severity scale for age-related macular degeneration: AREDS Report No.18. Arch Ophthalmol. 2005;123:1570-4.
29. Wray S, Kuwabara T, Sanderson P. Menkes' kinky hair disease: a light and electron microscopic study of the eye. Invest Ophthalmol. 1976;15:128-38.
30. Abugreen S, Muldrew KA, Stevenson MR, VanLeeuwen R, DeJong PT, Chakravarthy U. CNV subtype in first eyes predicts severity of ARM in fellow eyes. Br J Ophthalmol. 2003;87:307-11.
31. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL, 3rd. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology. 2005;112:533-9.
32. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye. 2005;19:935-44.
33. Age-Related Eye Disease Study Research Group, A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417-36.
34. Choroidal neovascularization in the Choroidal Neovascularization Prevention Trial, The Choroidal Neovascularization Prevention Trial Research Group. Ophthalmology. 1998;105:1364-72.
35. Complications of Age-Related Macular Degeneration Prevention Trial Study Group, The Complications of Age-Related Macular Degeneration Prevention Trial (CAPT): rationale, design and methodology. Clin Trials. 2004;1:91-107.
36. Friberg TR, Musch DC, Lim JI, Morse L, Freeman W, Sinclair S. Prophylactic treatment of age-related macular degeneration report number 1: 810-nanometer laser to eyes with drusen. Unilaterally eligible patients. Ophthalmology. 2006;113:622 e1.
37. Prenner JL, Rosenblatt BJ, Tolentino MJ, Ying GS, Javornik NB, Maguire MG, et al. Risk factors for choroidal neovascularization and vision loss in the fellow eye study of CNVPT. Retina. 2003;23:307-14.
38. Friberg TR and the PTAMD Study Group. The Prophylactic Treatment of AMD Multi-Centered Trial (PTAMD): Results From the Bilateral Study Arm. Invest Ophthalmol Vis Sci 2006; 47:E-Abstract 3538.
39. Argon laser photocoagulation for neovascular maculopathy, Three-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol. 1986; 104:694-701.
40. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration, Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1990;108:816-24.
41. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration, Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991;109:1220-31.
42. Han DP, Folk JC, Bratton AR. Visual loss after successful photocoagulation of choroidal neovascularization. Ophthalmology. 1988;95:1380-4.
43. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration, Macular Photocoagulation Study Group. Arch Ophthalmol. 1990;108:825-31.
44. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol. 1993;115:786-91.
45. Bressler NM, Bressler SB, Childs AL, Haller JA, Hawkins BS, Lewis H, et al. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology. 2004;111:1993-2006.
46. Hawkins BS, Bressler NM, Miskala PH, Bressler SB, Holekamp NM, Marsh MJ, et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology. 2004;111:1967-80.
47. Machemer R, Steinhorst UH. Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration? Graefes Arch Clin Exp Ophthalmol. 1993;231:635-41.
48. de Juan E Jr, Loewenstein A, Bressler NM, Alexander J. Translocation of the retina for management of subfoveal choroidal neovascularization II: a preliminary report in humans. Am J Ophthalmol. 1998;125:635-46.
49. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999;117:1329-45.
50. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000;45:195-214.
51. Verteporfin In Photodynamic Therapy Study Group, Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541-60.
52. Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No.3. Arch Ophthalmol. 2002;120:1443-54.
53. Stevenson MR, Hart PM, Chakravarthy U, Mackenzie G, Bird AC, Owens SL, et al. Visual functioning and quality of life in the SubFoveal Radiotherapy Study (SFRADS): SFRADS report 2. Br J Ophthalmol. 2005;89:1045-51.
54. Goverdhan SV, Gibbs FA, Lotery AJ. Radiotherapy for age-related macular degeneration: no more pilot studies please. Eye. 2005;19:1137-41.
55. Marcus DM, Peskin E, Maguire M, Weissgold D, Alexander J, Fine S, et al. The age-related macular degeneration radiotherapy trial (AMDRT): one year results from a pilot study. Am J Ophthalmol. 2004;138:818-28.
56. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004 30;351:2805-16.
57. Heier JS, Shapiro H, Singh AA. Randomized, Controlled Phase III Study of Ranibizumab (Lucentis™) for Minimally Classic or Occult Neovascular Age-Related Macular Degeneration: Two-Year Efficacy Results of the MARINA Study. Invest Ophthalmol Vis Sci 2006; 47:E-Abstract 2959.
58. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36: 331-5.
59. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-72 e5.
60. Vinores SA. Anecortave (Alcon Laboratories). IDrugs. 2005;8:327-34.
61. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology. 2003;110:2372-83; discussion 84-5.
62. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005;112:301-4.
63. Quiram PA, Gonzales CR, Schwartz SD. Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 2006;141:580-2.
64. Jonas JB, Kreissig I, Spandau UH, Harder B. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol. 2006;141: 579-80.
65. Guymer RH, Chiu AW, Lim L, Baird PN. HMG CoA reductase inhibitors (statins): do they have a role in age-related macular degeneration? Surv Ophthalmol. 2005;50:194-206.
66. Sarks S, Arnold J, Killingsworth M, Sarks J. Early drusen formation in the normal and aging eye and their relation to age-related maculopathy: a clinicopathological study. Br J Ophthalmol. 1999;83:358-68.
67. McConnell V, Silvestri G. Age-related macular degeneration. Ulster Med J. 2005;74:82-92.
68. Provis JM, Penfold PL, Cornish EE, Sandercoe TM, Madigan MC. Anatomy and development of the macula: specialisation and the vulnerability to macular degeneration. Clin Exp Optom. 2005;88:269-81.
69. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2006;51:137-52.
70. Arnold J, Sarks S. Age related macular degeneration. Clin Evid. 2004: 819-34.
71. Hageman G, Mullins R. Molecular composition of drusen as related to substructural phenotype. Mol Vis. 1999;5:28.
72. Sarraf D, Gin T, Yu F, Brannon A, Owens SL, Bird AC. Long-term drusen study. Retina. 1999;19:513-9.
73. Klein R, Klein B, Jensen S, Meuer S. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1997;104:7-21.
74. Spraul C, Grossniklaus H. Characteristics of drusen and Bruch's membrane in postmortem eyes with age-related macular degeneration. Arch Ophthalmol. 1997;115:267-73.
75. Sarks JP, Sarks SH, Killingsworth MC. Evolution of soft drusen in age-related macular degeneration. Eye. 1994;8(Pt 3), 269-83.
76. Guymer R, Bird A. Bruch's membrane, drusen, and age-related macular degeneration. In: Marmor M, Wolfensberger T, editors. The Retinal Pigment Epithelium. New York: Oxford University Press; 1998. p. 693-705.
77. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol. 2004 Apr;122:598-614.
78. Sivaprasad S, Bailey TA, Chong VN. Bruch's membrane and the vascular intima: is there a common basis for age-related changes and disease? Clin Experiment Ophthalmol. 2005;33:518-23.
79. Marshall J, Hussain A, Starita C, Moore D, Patmore A. The Retinal Pigment Epithelium. New York: Oxford University Press; 1998.
80. Guymer R, Luthert P, Bird A. Changes in Bruch's membrane and related structures with age. Prog Retin Eye Res. 1999;18:59-90.
81. Hogan M, Alvarado J. Studies on the human macula. Aging changes in Bruch's membrane. Arch Ophthalmol. 1967;77:410-20.
82. Sarks SH. Ageing and degeneration in the macular region: a clinico-pathological study. Br J Ophthalmol. 1976;60:324-41.
83. Green WR, McDonnell PJ, Yeo JH. Pathologic features of senile macular degeneration. Ophthalmology. 1985;92: 615-27.
84. Feeney-Burns L, Ellersieck M. Age-related changes in the ultrastructure of Bruch's membrane. Am J Ophthalmol. 1985;100:686-97.
85. Grindle C, Marshall J. Ageing changes in Bruch's membrane and their functional implications. Trans Ophthal Soc UK. 1978;98:172-5.
86. Pauleikhoff D, Sheraidah G, Marshall J, Bird A, Wessing A. Biochemical and histochemical analysis of age related lipid deposits in Bruch's membrane. Ophthalmologe. 1994;91:730-4.
87. Handa JT, Verzijl N, Matsunaga H, Aotaki-Keen A, Lutty GA, te Koppele JM, et al. Increase in the advanced glycation end product pentosidine in Bruch's membrane with age. Invest Ophthalmol Vis Sci. 1999;40:775-9.
88. Curcio C, Millican C, Bailey T, Kruth H. Accumulation of cholesterol with age in human Bruch's membrane. Invest Ophthalmol Vis Sci. 2001;42:265-74.
89. Kamei M, Hollyfield J. TIMP-3 in Bruch's membrane: changes during aging and in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1999;40:2367-75.
90. Newsome D, Huh W, Green W. Bruch's membrane age-related changes vary by region. Curr Eye Res. 1987;6:1211-21.
91. Ishibashi T, Murata T, Hangai M, Nagai R, Horiuchi S, Lopez P, et al. Advanced glycation end products in age-related macular degeneration. Arch Ophthalmol. 1998;116:1629-32.
92. Hewitt A, Nakazawa K, Newsome D. Analysis of newly synthesized Bruch's membrane proteoglycans. Invest Ophthalmol Vis Sci. 1989;30:478-86.
93. Karwatowski W, Jeffries T, Duance V, Albon J, Bailey A, Easty D. Preparation of Bruch's membrane and analysis of the age-related changes in the structural collagens. Br J Ophthalmol. 1995;79:944-52.
94. Haimovici R, Gantz DL, Rumelt S, Freddo TF, Small DM. The lipid composition of drusen, Bruch's membrane, and sclera by hot stage polarizing light microscopy. Invest Ophthalmol Vis Sci. 2001;42:1592-9.
95. Li CM, Chung BH, Presley JB, Malek G, Zhang X, Dashti N, et al. Lipoprotein-like particles and cholesteryl esters in human Bruch's membrane: initial characterization. Invest Ophthalmol Vis Sci. 2005;46:2576-86.
96. Starita C, Hussain A, Pagliarini S, Marshall J. Hydrodynamics of ageing Bruch's membrane: implications for macular disease. Exp Eye Res. 1996;62:565-72.
97. Moore D, Clover G. The effect of age on the macromolecuar permeability of human Bruch's membrane. Invest Ophthalmol Vis Sci. 2001;42:2970-5.
98. Hussain A, Rowe L, Marshall J. Age-related alterations in the diffusional transport of amino acids across the human Bruch's-choroid complex. J Opt Soc Am A Opt Image Sci Vis. 2002;19:166-72.
99. Moore D, Hussain A, Marshall J. Age-related variation in the hydraulic conductivity of Bruch's membrane. Invest Ophthalmol Vis Sci. 1995;36:1290-7.
100. Chong NH, Keonin J, Luthert PJ, Frennesson CI, Weingeist DM, Wolf RL, et al. Decreased thickness and integrity of the macular elastic layer of Bruch's membrane correspond to the distribution of lesions associated with age-related macular degeneration. Am J Pathol. 2005;166:241-51.
101. Nackman G, Karkowski F, Halpern V, Gaetz H, Tilson M. Elastin degradation products induce adventitial angiogenesis in the Anidjar/Dobrin rat aneurysm model. Surgery. 1997;122:39-44.
102. Kamisato S, Uemura Y, Takami N, Okamoto K. Involvement of intracellular cyclic GMP and cyclic GMP-dependent protein kinase in alpha-elastin-induced macrophage chemotaxis. J Biochem (Tokyo). 1997;121:862-7.
103. Marshall J, Hussain A, Starita C, Moore D, Patmore A. Aging and Bruch's membrane. In: Marmor M, Wolfensberger T, editors. The Retinal Pigment Epithelium. New York: Oxford University Press; 1998. p. 669-92.
104. Holz F, Sheraiadah G, Pauleikhoff D, Marshall J, Bird A. Analysis of lipid deposits extracted from human macular and peripheral Bruch's membrane. Arch Ophthalmol. 1994;112:402-6.
105. Pauleikhoff D, Harper C, Marshall J, Bird A. Aging changes in Bruch's membrane. Ophthalmology. 1990;97:171-8.
106. Anderson D, Ozaki S, Nealon M, Neitz J, Mullins R, Hageman G, et al. Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: Implications for the process of drusen formation. Am J Ophthalmol. 2001;131:767-81.
107. Farkas T, Sylvester V, Archer D, Altona M. The histochemistry of drusen. Am J Ophthalmol. 1971;71:1206-15.
108. Green WR, Enger C. Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture. Ophthalmology. 1993;100:1519-35.
109. Kliffen M, van der Schaft TL, Mooy CM, de Jong PT. Morphologic changes in age-related maculopathy. Microsc Res Tech. 1997;36:106-22.
110. Feher J, Valu L. [On the structure of Bruch's membrane]. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1967;173:162-7.
111. Loffler KU, Lee WR. Basal linear deposit in the human macula. Graefes Arch Clin Exp Ophthalmol. 1986;224:493-501.
112. van der Schaft TL, de Bruijn WC, Mooy CM, Ketelaars DA, de Jong PT. Is basal laminar deposit unique for age-related macular degeneration? [see comments]. Arch Ophthalmol. 1991;109:420-5.
113. van der Schaft T, Mooy C, de Bruijn W, Oron F, Mulder P, de Jong P. Histological features of age-related macular degeneration. A statistical analysis. Ophthalmology. 1992;99:278-86.
114. Spraul CW, Lang GE, Grossniklaus HE. Morphometric analysis of the choroid, Bruch's membrane, and retinal pigment epithelium in eyes with age-related macular degeneration [see comments]. Invest Ophthalmol Vis Sci. 1996;37:2724-35.
115. Milam AH, Curcio CA, Cideciyan AV, Saxena S, John SK, Kruth HS, et al. Dominant late-onset retinal degeneration with regional variation of sub-retinal pigment epithelium deposits, retinal function, and photoreceptor degeneration. Ophthalmology. 2000;107:2256-66.
116. Kliffen M, Mooy CM, Luider TM, Huijmans JG, Kerkvliet S, de Jong PT. Identification of glycosaminoglycans in age-related macular deposits. Arch Ophthalmol. 1996;114:1009-14.
117. Kliffen M, Mooy CM, Luider TM, de Jong PT. Analysis of carbohydrate structures in basal laminar deposit in aging human maculae. Invest Ophthalmol Vis Sci. 1994;35:2901-5.
118. van der Schaft T, Mooy C, de Bruijn W, Bosman F, de Jong P. Immunohistochemical light and electron microscopy of basal laminar deposit. Graefes Arch Clin Exp Ophthalmol. 1994;232:40-6.
119. Knupp C, Amin S, Munro P, Luthert P, Squire J. Collagen VI assemblies in age-related macular degeneration. J Struct Biol. 2002;139:181-9.
120. Curcio CA, Presley JB, Millican CL, Medeiros NE. Basal deposits and drusen in eyes with age-related maculopathy: evidence for solid lipid particles. Exp Eye Res. 2005;80: 761-75.
121. Sarks S, Van Driel D, Maxwell L, Killingsworth M. Softening of drusen and subretinal neovascularization. Trans Ophthalmol Soc U K. 1980;100:414-22.
122. Okubo A, Rosa R, Bunce C, Alexander R, Fan J, Bird A, et al. The relationships of age changes in retinal pigment epithelium and Bruch's membrane. Invest Ophthalmol Vis Sci. 1999;40:443-9.
123. Hogan M. Role of the retinal pigment epithelium in macular disease. Trans Am Acad Ophthalmol Otolaryngol. 1972;76:64-80.
124. Bird A. Pathophysiology of AMD. In: Hampton GR, Nelsen PT, editors. Age-related macular degeneration: principles and practice. New York: Raven Press; 1992. Chapter 3.
125. Dorey C, Wu G, Ebenstein D. Cell loss in the aging retina: Relationship to lipofuscin accumulation and macular degeneration. Invest Ophthalmol Vis Sci. 1989;30:1691-9.
126. Bird AC. Bruch's membrane change with age. Br J Ophthalmol. 1992;76:166-8.
127. Katz ML, Robison WG Jr. Age-related changes in the retinal pigment epithelium of pigmented rats. Exp Eye Res. 1984;38:137-51.
128. Feeney-Burns L, Hilderbrand E, Eldridge S. Aging human RPE: morphometric analysis of macular, equatorial and peripheral cells. Invest Ophthalmol Vis Sci. 1984;25: 195-200.
129. Wing G, Blanchard G, Weiter J. Topography and age relationship of lipofuscin concentration in the RPE. Invest Ophthalmol Vis Sci. 1978;7:601-7.
130. Rozanowska M, Jarvis-Evans J, Korytowski W, Boulton ME, Burke JM, Sarna T. Blue light-induced reactivity of retinal age pigment. In vitro generation of oxygen-reactive species. J Biol Chem. 1995;270:18825-30.
131. Holz F, Bellman C, Staudt S, Schutt F, Volcker H. Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2001;42:1051-6.
132. Katz ML. Potential role of retinal pigment epithelial lipofuscin accumulation in age-related macular degeneration. Arch Gerontol Geriatr. 2002;34:359-70.
133. Sparrow JR, Boulton M. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res. 2005;80:595-606.
134. Ramrattan R, van der Schaft T, Mooy C, de Bruijn W, Mulder P, de Jong P. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci. 1994;35:2857-64.
135. McLeod DS, Taomoto M, Otsuji T, Green WR, Sunness JS, Lutty GA. Quantifying changes in RPE and choroidal vasculature in eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2002 Jun;43:1986-93.
136. Midena E, Segato T, Blarzino MC, Degli Angeli C. Macular drusen and the sensitivity of the central visual field. Doc Ophthalmol. 1994;88:179-85.
137. Curcio C, Medeiros N, Millican C. Photoreceptor loss in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1996;37:1236-49.
138. Jackson GR, Owsley C. Visual dysfunction, neurodegenerative diseases, and aging. Neurol Clin. 2003;21:709-28.
139. Li J, Tso MO, Lam TT. Reduced amplitude and delayed latency in foveal response of multifocal electroretinogram in early age related macular degeneration. Br J Ophthalmol. 2001;85:287-90.
140. Owsley C, Jackson GR, Cideciyan AV, Huang Y, Fine SL, Ho AC, et al. Psychophysical evidence for rod vulnerability in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2000;41:267-73.
141. Jackson GR, Owsley C, Curcio CA. Photoreceptor degeneration and dysfunction in aging and age-related maculopathy. Ageing Res Rev. 2002;1:381-96.
142. Owsley C, Jackson GR, White M, Feist R, Edwards D. Delays in rod-mediated dark adaptation in early age-related maculopathy. Ophthalmology. 2001;108:1196-202.
143. Jackson GR, McGwin G Jr, Phillips JM, Klein R, Owsley C. Impact of aging and age-related maculopathy on activation of the a-wave of the rod-mediated electroretinogram. Invest Ophthalmol Vis Sci. 2004;45:3271-8.
144. Owsley C, McGwin G, Jackson GR, Heimburger DC, Piyathilake CJ, Klein R, et al. Effect of short-term, high-dose retinol on dark adaptation in aging and early age-related maculopathy. Invest Ophthalmol Vis Sci. 2006;47:1310-8.
145. Stangos N, Voutas S, Topouzis F, Karampatakis V. Contrast sensitivity evaluation in eyes predisposed to age-related macular degeneration and presenting normal visual acuity. Ophthalmologica. 1995;209:194-8.
146. Sunness J, Massof R, Johnson M, Bressler N, Bressler S, Fine S. Diminished foveal sensitivity may predict the development of advanced age-related macular degeneration. Ophthalmology. 1989;96:375-81.
147. Kleiner RC, Enger C, Alexander MF, Fine SL. Contrast sensitivity in age-related macular degeneration. Arch Ophthalmol. 1988;106:55-7.
148. Sandberg MA, Gaudio AR. Slow photostress recovery and disease severity in age-related macular degeneration. Retina. 1995;15:407-12.
149. Eisner A, Klein ML, Zilis JD, Watkins MD. Visual function and the subsequent development of exudative age-related macular degeneration. Invest Ophthalmol Vis Sci. 1992;33:3091-102.
150. Eisner A, Stoumbos VD, Klein ML, Fleming SA. Relations between fundus appearance and function. Eyes whose fellow eye has exudative age-related macular degeneration. Invest Ophthalmol Vis Sci. 1991;32:8-20.
151. Johnson PT, Brown MN, Pulliam BC, Anderson DH, Johnson LV. Synaptic pathology, altered gene expression, and degeneration in photoreceptors impacted by drusen. Invest Ophthalmol Vis Sci. 2005;46:4788-95.
152. Johnson PT, Lewis GP, Talaga KC, Brown MN, Kappel PJ, Fisher SK, et al. Drusen-associated degeneration in the retina. Invest Ophthalmol Vis Sci. 2003;44:4481-8.
153. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the rpe-bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20:705-32.
154. Anderson D, Mullins R, Hageman G, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134:411-31.
155. Killingsworth M, Sarks J, Sarks S. Macrophages related to Bruch's membrane in age-related macular degeneration. Eye. 1990;4:613-21.
156. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and Aetiological Aspects of Macular Degeneration. Progress in Retinal Research. London: Elsevier Science Ltd; 2001. p. 385-414.
157. Heriot W, Henkind P, Bellhorn R, Burns M. Choroidal neovascularization can digest Bruch's membrane. A prior break is not essential. Ophthalmology. 1984;91:1603-8.
158. Penfold P, Killingsworth M, Sarks S. An ultrastructural study of the role of leucocytes and fibroblasts in the breakdown of Bruch's membrane. Aust J Ophthalmol. 1984;12:23-31.
159. Dastgheib K, Green W. Granulomatous reaction to Bruch's membrane in age-related macular degeneration. Arch Ophthalmol. 1994;112:813-8.
160. Hageman G, Mullins R, Russell S, Johnson L, Anderson D. Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells. FASEB J. 1999;13:477-84.
161. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000;14:835-46.
162. Johnson L, Ozaki S, Staples M, Erickson P, Anderson D. A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res. 2000;70:441-9.
163. Johnson L, Leitner W, Staples M, Anderson D. Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Exp Eye Res. 2001;73:887-96.
164. Mullins RF, Johnson LV, Anderson DH, Hageman GS. Characterization of drusen-associated glycoconjugates. Ophthalmology. 1997;104:288-94.
165. Russell SR, Mullins RF, Schneider BL, Hageman GS. Location, substructure, and composition of basal laminar drusen compared with drusen associated with aging and age-related macular degeneration. Am J Ophthalmol. 2000;129:205-14.
166. Mullins RF, Aptsiauri N, Hageman GS. Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye. 2001;15(Pt 3): 390-5.
167. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer's A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A. 2002;99:11830-5.
168. Malek G, Li CM, Guidry C, Medeiros NE, Curcio CA. Apolipoprotein B in cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy. Am J Pathol. 2003;162:413-25.
169. Anderson D, Talaga K, Rivest A, Barron E, Hageman G, Johnson L. Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res. 2004;78:243-56.
170. Peto T, Lengyel I, Frederickson C, Vankuijk F. Zinc in Drusen. Invest Ophthalmol Vis Sci 2005; 46:E-Abstract 3008.
171. Holers VM. The complement system as a therapeutic target in autoimmunity. Clin Immunol. 2003;107:140-51.
172. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science. 1996;272:50-3.
173. Mastellos D, Andronis C, Persidis A, Lambris JD. Novel biological networks modulated by complement. Clin Immunol. 2005;115:225-35.
174. Mastellos D, Germenis AE, Lambris JD. Complement: an inflammatory pathway fulfilling multiple roles at the interface of innate immunity and development. Curr Drug Targets Inflamm Allergy. 2005;4):125-7.
175. Walport MJ. Complement. Second of two parts. N Engl J Med. 2001;344:1140-4.
176. Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344:1058-66.
177. Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol. 2006;176:1305-10.
178. Pio R, Martinez A, Unsworth EJ, Kowalak JA, Bengoechea JA, Zipfel PF, et
179. Holers VM, Thurman JM. The alternative pathway of complement in disease: opportunities for therapeutic targeting. Mol Immunol. 2004;41:147-52.
180. Song WC. Membrane complement regulatory proteins in autoimmune and inflammatory tissue injury. Curr Dir Autoimmun. 2004;7:181-99.
181. Zipfel PF, Heinen S, Jozsi M, Skerka C. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol. 2006;43:97-106.
182. Halstensen TS, Mollnes TE, Fausa O, Brandtzaeg P. Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon. Gut. 1989;30:361-6.
183. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683-747.
184. Lassmann H. Recent neuropathological findings in MS-implications for diagnosis and therapy. J Neurol. 2004 Sep;251Suppl 4: IV2-5.
185. Neumann E, Barnum SR, Tarner IH, Echols J, Fleck M, Judex M, et al. Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum. 2002;46:934-45.
186. Tang S, Lui SL, Lai KN. Pathogenesis of lupus nephritis: an update. Nephrology (Carlton). 2005;10:174-9.
187. Turnberg D, Cook HT. Complement and glomerulonephritis: new insights. Curr Opin Nephrol Hypertens. 2005;14:223-8.
188. Gerard NP, Gerard C. Complement in allergy and asthma. Curr Opin Immunol. 2002;14:705-8.
189. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol. 2004;41:355-67.
190. Pangburn MK, Pangburn KL, Koistinen V, Meri S, Sharma AK. Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement. J Immunol. 2000;164:4742-51.
191. Zipfel PF. Complement factor H: physiology and pathophysiology. Semin Thromb Hemost. 2001;27:191-9.
192. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005;102:7227-32.
193. Johnson LV, Talaga KC, Rivest AJ, Staples MK, Radeke MJ, Barron E, et al. Characterization of Beta Amyloid-Containing Vesicles within Drusen. Invest Ophthalmol Vis Sci 2003; 44:E-Abstract 4229.
194. Hageman G, Luthert P, Chong N, Johnson L, Anderson D, Mullins R. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPEBruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20:705-32.
195. Miller DM, Espinosa-Heidmann DG, Legra J, Dubovy SR, Suner IJ, Sedmak DD, et al. The association of prior cytomegalovirus infection with neovascular age-related macular degeneration. Am J Ophthalmol. 2004;138:323-8.
196. Klein M, Mauldin W, Stoumbos V. Heredity and age-related macular degeneration. Observations in monozygotic twins. Arch Ophthalmol. 1994;112:932-7.
197. Heiba I, Elston R, Klein B, Klein R. Sibling correlations and segregation analysis of age-related maculopathy: the Beaver Dam Eye Study. Genet Epidemiol. 1994;11:51-67.
198. Seddon J, Ajani U, Mitchell B. Familial aggregation of age-related maculopathy. Am J Ophthalmol. 1997;123:199-206.
199. Meyers SM, Greene T, Gutman FA. A twin study of age-related macular degeneration. Am J Ophthalmol. 1995;120:757-66.
200. Hammond CJ, Webster AR, Snieder H, Bird AC, Gilbert CE, Spector TD. Genetic influence on early age-related maculopathy: a twin study. Ophthalmology. 2002;109:730-6.
201. Abecasis GR, Yashar BM, Zhao Y, Ghiasvand NM, Zareparsi S, Branham KE, et al. Age-related macular degeneration: a high-resolution genome scan for susceptibility loci in a population enriched for late-stage disease. Am J Hum Genet. 2004;74:482-94.
202. Iyengar SK, Song D, Klein BE, Klein R, Schick JH, Humphrey J, et al. Dissection of genomewide-scan data in extended families reveals a major locus and oligogenic susceptibility for age-related macular degeneration. Am J Hum Genet. 2004;74:20-39.
203. Klein ML, Schultz DW, Edwards A, Matise TC, Rust K, Berselli CB, et al. Age-related macular degeneration. Clinical features in a large family and linkage to chromosome 1q. Arch Ophthalmol. 1998;116:1082-8.
204. Majewski J, Schultz DW, Weleber RG, Schain MB, Edwards AO, Matise TC, et al. Age-related macular degeneration-a genome scan in extended families. Am J Hum Genet. 2003;73:540-50.
205. Schick JH, Iyengar SK, Klein BE, Klein R, Reading K, Liptak R, et al. A whole-genome screen of a quantitative trait of age-related maculopathy in sibships from the Beaver Dam Eye Study. Am J Hum Genet. 2003;72:1412-24.
206. Seddon JM, Santangelo SL, Book K, Chong S, Cote J. A genomewide scan for age-related macular degeneration provides evidence for linkage to several chromosomal regions. Am J Hum Genet. 2003;73:780-90.
207. Weeks DE, Conley YP, Mah TS, Paul TO, Morse L, Ngo-Chang J, et al. A full genome scan for age-related maculopathy. Hum Mol Genet. 2000;9:1329-49.
208. Weeks DE, Conley YP, Tsai HJ, Mah TS, Rosenfeld PJ, Paul TO, et al. Age-related maculopathy: an expanded genome-wide scan with evidence of susceptibility loci within the 1q31 and 17q25 regions. Am J Ophthalmol. 2001;132:682-92.
209. Weeks DE, Conley YP, Tsai HJ, Mah TS, Schmidt S, Postel EA, et al. Age-Related Maculopathy: A Genomewide Scan with Continued Evidence of Susceptibility Loci within the 1q31, 10q26, and 17q25 Regions. Am J Hum Genet. 2004;75(2):174-89.
210. Fisher SA, Abecasis GR, Yashar BM, Zareparsi S, Swaroop A, Iyengar SK, et al. Meta-analysis of genome scans of age-related macular degeneration. Hum Mol Genet. 2005;14:2257-64.
211. Schultz D, Klein M, Humpert A, Luzier C, Persun V, Schain M, et al. Analysis of the ARMD1 locus: Evidence that a mutation in HEMICENTIN-1 is associated with age-related macular degeneration in a large family. Hum Mol Genet. 2003;12:3315-23.
212. Conley YP, Thalamuthu A, Jakobsdottir J, Weeks DE, Mah T, Ferrell RE, et al. Candidate gene analysis suggests a role for fatty acid biosynthesis and regulation of the complement system in the etiology of age-related maculopathy. Hum Mol Genet. 2005;14:1991-2002.
213. Haines JL, Schnetz-Boutaud N, Schmidt S, Scott WK, Agarwal A, Postel EA, et al. Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6. Invest Ophthalmol Vis Sci. 2006;47:329-35.
214. Stone EM, Braun TA, Russell SR, Kuehn MH, Lotery AJ, Moore PA, et al. Missense variations in the fibulin 5 gene and age-related macular degeneration. N Engl J Med. 2004;351:346-53.
215. Zareparsi S, Buraczynska M, Branham KE, Shah S, Eng D, Li M, et al. Toll-like receptor 4 variant D299G is associated with susceptibility to age-related macular degeneration. Hum Mol Genet. 2005;14:1449-55.
216. Souied EH, Benlian P, Amouyel P, Feingold J, Lagarde JP, Munnich A, et al. The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration. Am J Ophthalmol. 1998;125:353-9.
217. Klaver CC, Kliffen M, van Duijn CM, Hofman A, Cruts M, Grobbee DE, et al. Genetic association of apolipoprotein E with age-related macular degeneration. Am J Hum Genet. 1998;63:200-6.
218. Baird PN, Guida E, Chu DT, Vu HT, Guymer RH. The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2004;45:1311-5.
219. Allikmets R, Shroyer N, Singh N, Seddon J, Lewis R, Bernstein P, et al. Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science. 1997;277:1805-7.
220. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al., 2005 15, Complement factor H polymorphism in age-related macular degeneration. Science. 2005 15;308:385-9.
221. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421-4.
222. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419-21.
223. Zareparsi S, Branham KE, Li M, Shah S, Klein RJ, Ott J, et al. Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Hum Genet. 2005;77:149-53.
224. Magnusson KP, Duan S, Sigurdsson H, Petursson H, Yang Z, Zhao Y, et al. CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med. 2006;3:e5.
225. Sepp T, Khan JC, Thurlby DA, Shahid H, Clayton DG, Moore AT, et al. Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers. Invest Ophthalmol Vis Sci. 2006;47:536-40.
226. Souied EH, Leveziel N, Richard F, Dragon-Durey MA, Coscas G, Soubrane G, et al. Y402H complement factor H polymorphism associated with exudative age-related macular degeneration in the French population. Mol Vis. 2005;11:1135-40.
227. Okamoto H, Umeda S, Obazawa M, Minami M, Noda T, Mizota A, et al. Complement factor H polymorphisms in Japanese population with age-related macular degeneration. Mol Vis. 2006;12:156-8.
228. Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006;38:458-62.
229. Lokki ML, Koskimies SA. Allelic differences in hemolytic activity and protein concentration of BF molecules are found in association with particular HLA haplotypes. Immunogenetics. 1991;34:242-6.
230. Jakobsdottir J, Conley YP, Weeks DE, Mah TS, Ferrell RE, Gorin MB. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet. 2005;77: 389-407.
231. Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet. 2005;14:3227-36.
232. Schmidt S, Hauser MA, Scott WK, Postel EA, Agarwal A, Gallins P, et al. Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. Am J Hum Genet. 2006;78:852-64.
233. Saunders RE, Goodship TH, Zipfel PF, Perkins SJ. An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations. Hum Mutat. 2006;27:21-30.
234. Heinen S, Sanchez-Corral P, Jackson MS, Strain L, Goodship JA, Kemp EJ, et al. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat. 2006;27:292-3.
235. Warwicker P, Goodship TH, Donne RL, Pirson Y, Nicholls A, Ward RM, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 1998;53:836-44.
236. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Carreras Berges L, Lopez-Trascasa M, Sanchez-Corral P, et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet. 2005;14:703-12.
237. Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet. 2003;12:3385-95.
238. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, et al. Genetics of HUS: the impact of MCP, CFH and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267-79.
239. Atkinson JP, Liszewski MK, Richards A, Kavanagh D, Moulton EA. Hemolytic uremic syndrome: an example of insufficient complement regulation on self-tissue. Ann N Y Acad Sci. 2005;1056:144-52.
240. Abrera-Abeleda MA, Nishimura C, Smith JL, Sethi S, McRae JL, Murphy BF, et al. Variations in the Complement Regulatory Genes Factor H (CFH) and Factor H Related 5 (CFHR5) are Associated with Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease). J Med Genet. 2006;43:582-9.
241. Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol. 2005;16:1392-403.
242. Robman L, Mahdi O, McCarty C, Dimitrov P, Tikellis G, McNeil J, et al. Exposure to Chlamydia pneumoniae infection and progression of age-related macular degeneration. Am J Epidemiol. 2005;161:1013-9.
243. Erkkila H, Raitta C, Niemi K. Ocular findings in four siblings with pseudoxanthoma elasticum. Acta Ophthalmol (Copenh). 1983;61:589-99.
244. Zee RY, Diehl KA, Ridker PM. Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: A nested case-control study. Atherosclerosis. 2006;187:332-5.